Ginkgo Bioworks Holdings, Inc. (DNA) |
|
2 0.04 (2.04%)
|
02-07 16:00 |
|
Open: |
1.94 |
Pre. Close: |
1.96 |
|
High:
|
2.02 |
Low:
|
1.9 |
|
Volume:
|
19,641,476 |
Market Cap:
|
3,963(M) |
|
|
|
Technical analysis |
as of: 2023-02-07 4:27:45 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 2.62 One year: 3.06 |
| Support: |
Support1: 1.75 Support2: 1.45 |
| Resistance: |
Resistance1: 2.25 Resistance2: 2.62 |
| Pivot: |
1.88 |
| Moving Average: |
MA(5): 2.04 MA(20): 1.85
MA(100): 2.26  MA(250): 2.82 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 60.1 %D(3): 71 |
| RSI: |
RSI(14): 55.4 |
| 52-week: |
High: 5.55 Low: 1.45 |
| Average Vol(K): |
3-Month: 23,223 (K) 10-Days: 19,996 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DNA ] has closed below upper band by 29.5%. Bollinger Bands are 14.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.02 - 2.03 |
2.03 - 2.04 |
|
Low:
|
1.88 - 1.89 |
1.89 - 1.9 |
|
Close:
|
1.98 - 2 |
2 - 2.02 |
|
Company Description |
|
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. |
Headline News |
Wed, 08 Feb 2023
Two for One: Simultaneous Sequencing of Genetic and Epigenetic ... - Genetic Engineering & Biotechnology News
Tue, 07 Feb 2023
Sailor who died in Pearl Harbor attack identified through DNA testing - New York Post
Tue, 07 Feb 2023
Russia Legalizes Massive DNA Collection Without Oversight - Human Rights Watch
Tue, 07 Feb 2023
Adopted Woman Backed Over Why She Wants Fiancé to Take a DNA test - Newsweek
Tue, 07 Feb 2023
Illumina Attracts Challengers for DNA Sequencing Ahead of Earnings - Barron's
Mon, 06 Feb 2023
How relatively new DNA technology helped solve Lexington serial rape case - LEX 18 News - Lexington, KY
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
1,470 (M) |
| Shares Float |
738 (M) |
|
% Held by Insiders
|
12.8 (%) |
|
% Held by Institutions
|
94 (%) |
|
Shares Short
|
125,510 (K) |
|
Shares Short P.Month
|
114,290 (K) |
Stock Financials |
|
EPS
|
-1.68 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.87 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-692.9 |
|
Return on Assets (ttm)
|
-113.7 |
|
Return on Equity (ttm)
|
-231.4 |
|
Qtrly Rev. Growth
|
-14.4 |
|
Gross Profit (p.s.)
|
0.12 |
|
Sales Per Share
|
0.35 |
|
EBITDA (p.s.)
|
-2.47 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-313 (M) |
|
Levered Free Cash Flow
|
1,140 (M) |
Stock Valuations |
|
PE Ratio
|
-1.2 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.29 |
|
Price to Sales
|
5.56 |
|
Price to Cash Flow
|
-9.4 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
